Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05366439 · ClinicalTrials.gov registry record · Phase 1

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

A Phase 1 study, sponsored by Atea Pharmaceuticals.

Terminated
Registry status
Phase 1
Development phase
5
Enrollment target

NCT05366439 is a Phase 1 study that was terminated before completion, run by Atea Pharmaceuticals. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05366439, a Phase 1 study, was terminated before completion, sponsored by Atea Pharmaceuticals.

TERMINATED
Registry status
Phase 1
Development phase
5 participants
Enrollment target

Study Summary

This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

Interventions

  • DRUG Placebo Comparator
  • DRUG AT-752

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2022-04-22
Est. Completion 2023-03-16
Phase Phase 1

Sponsor

Atea Pharmaceuticals

12 total trials

What the Registry Record Tells You About NCT05366439

The ClinicalTrials.gov registry entry for NCT05366439 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.

NCT05366439 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05366439 about?

NCT05366439 is a clinical study titled "Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model". This study will assess the safety and antiviral activity of AT-752 in healthy subjects in a Dengue Human Challenge Model

What is the current status of trial NCT05366439?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-04-22. Estimated completion is 2023-03-16.

What interventions are being tested in trial NCT05366439?

The interventions under investigation include: Placebo Comparator (DRUG), AT-752 (DRUG).

Who is sponsoring clinical trial NCT05366439?

This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.